Armistice Capital, Llc - Jul 30, 2021 Form 4 Insider Report for EYEGATE PHARMACEUTICALS INC (KPRX)

Role
10%+ Owner
Signature
ARMISTICE CAPITAL, LLC by /s/ Steven Boyd, Managing Member
Stock symbol
KPRX
Transactions as of
Jul 30, 2021
Transactions value $
-$646,608
Form type
4
Date filed
8/3/2021, 05:09 PM
Previous filing
Jul 29, 2021
Next filing
Aug 6, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPRX Common Stock Sale -$184K -68.2K -6.52% $2.69 978K Jul 30, 2021 See Footnote F1, F2
transaction KPRX Common Stock Sale -$463K -193K -19.72% $2.40 785K Aug 2, 2021 See Footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities of EyeGate Pharmaceuticals, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.6145 to $2.7604, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.3595 to $2.5144, inclusive.